pbk Antibody

What is PBK/TOPK and what are its primary functions in cellular biology?

PBK/TOPK is a serine/threonine kinase that plays several important roles in cellular function. It phosphorylates MAP kinase p38 and appears to be active primarily during mitosis, suggesting a critical role in cell cycle regulation and mitotic progression. Additionally, PBK may contribute to the activation of lymphoid cells, indicating its importance in immune function. When phosphorylated, PBK forms a complex with TP53, leading to TP53 destabilization and attenuation of the G2/M checkpoint during DNA damage responses, such as those induced by doxorubicin treatment .

PBK has multiple aliases in the literature, including TOPK, Lymphokine-activated killer T-cell-originated protein kinase, Cancer/testis antigen 84, MAPKK-like protein kinase, Nori-3, Spermatogenesis-related protein kinase, and CT84 . The protein has a predicted molecular weight of approximately 36-40 kDa when analyzed by Western blotting .

What applications are PBK antibodies typically used for in research?

PBK antibodies are employed across multiple experimental applications in molecular and cellular biology research. The most common applications include:

• Western Blotting (WB): For detecting and quantifying PBK protein expression levels in cell or tissue lysates. This technique allows researchers to evaluate protein size and relative abundance .

• Immunohistochemistry (IHC): For visualizing PBK expression patterns in tissue sections, which is particularly important for cancer studies. This allows assessment of protein localization within tissue architecture and cellular compartments .

• Immunofluorescence (IF/ICC): For subcellular localization studies, revealing whether PBK is predominantly nuclear, cytoplasmic, or both. This technique provides higher resolution of protein localization than IHC .

• Immunoprecipitation (IP): For isolating PBK protein complexes to study protein-protein interactions .

• Flow Cytometry (FACS): For measuring PBK expression in individual cells within heterogeneous populations .

• ELISA: For quantitative measurement of PBK in solution .

Each application requires specific optimization and validation protocols to ensure reliable results.

How should researchers select the appropriate PBK antibody for their experimental needs?

Selection of an appropriate PBK antibody depends on several critical factors:

• Target species: Ensure the antibody reacts with your species of interest. Available PBK antibodies show reactivity with human, mouse, and/or rat samples .

• Application compatibility: Verify that the antibody has been validated for your specific application. Some antibodies perform well in multiple applications (e.g., WB, IHC, and IF), while others are optimized for specific techniques .

• Epitope recognition: Consider which region of PBK the antibody targets. Different antibodies recognize different amino acid sequences, which can affect detection in certain contexts:

  • N-terminal targeting (e.g., AA 1-110)

  • Middle region targeting (e.g., AA 122-229)

  • C-terminal targeting (e.g., AA 251-322)

• Clonality:

  • Monoclonal antibodies (e.g., clones 2C8, 3A11, 2D6) provide high specificity for a single epitope and consistent lot-to-lot reproducibility .

  • Polyclonal antibodies often provide higher sensitivity by recognizing multiple epitopes but may have greater lot-to-lot variation .

• Host species: Consider the host animal (mouse, rabbit) in relation to other antibodies you may be using in multiplex experiments to avoid cross-reactivity .

• Validation evidence: Review published literature and manufacturer data that demonstrate antibody specificity, such as knockout controls or immunoprecipitation results .

What is the typical expression pattern of PBK in normal versus cancerous tissues?

PBK expression shows distinct patterns between normal and cancerous tissues, making it a potential biomarker for cancer research:

• Normal tissues: PBK expression is generally low in most adult differentiated tissues. It is more commonly expressed in tissues with high proliferative capacity, such as testis and certain immune cells during activation .

• Cancer tissues: PBK is frequently overexpressed in various cancer types, including:

  • Colon cancer

  • Breast cancer

  • Glioblastoma

  • Cervical cancer (as evidenced by expression in HeLa cells)

  • Epidermoid carcinoma (as evidenced by expression in A431 cells)

• Subcellular localization: PBK protein can be localized in either the nucleus or cytoplasm, or both, depending on the cell type and condition . This localization pattern may have functional significance and can be assessed using immunohistochemistry or immunofluorescence techniques.

• Scoring systems: Researchers often use semi-quantitative scoring systems to evaluate PBK expression in tissue samples. One approach involves:

  • Scoring staining intensity: colorless (0), pale-yellow (1), brownish-yellow (2), brown (3)

  • Scoring percentage of positive cells: 1-10% (1), 11-50% (2), 51-80% (3), >80% (4)

  • Calculating an immunization score by multiplying these values

  • Categorizing expression as negative (-), low (+), or high (++)

What methodological considerations are important for optimizing PBK antibody performance in immunohistochemistry?

Optimizing PBK antibody performance in immunohistochemistry requires attention to several methodological details:

• Fixation methods:

  • Formalin-fixed paraffin-embedded (FFPE) tissues are commonly used, but fixation time can impact epitope accessibility

  • Antigen retrieval methods should be optimized to ensure proper unmasking of PBK epitopes without compromising tissue integrity

  • For Cell Signaling Technology's PBK/TOPK antibody (#4942), a dilution of 1:50 is recommended for paraffin-embedded sections

• Detection systems:

  • Signal amplification methods may be necessary for detecting low-abundance PBK

  • For nuclear staining evaluation, counterstains should be carefully selected to allow clear visualization of PBK-positive nuclei

• Controls:

  • Positive controls should include tissues known to express PBK (e.g., testicular tissue or specific cancer cell lines)

  • Negative controls should include primary antibody omission and ideally PBK-knockout tissues

  • Sequential tissue sections should be used for comparing different antibodies or conditions

• Scoring and quantification:

  • Implement a systematic scoring approach, such as the method described where both staining intensity and percentage of positive cells are evaluated:

    • Color intensity: 0 (colorless) to 3 (brown)

    • Percentage of positive cells: 1 (1-10%) to 4 (>80%)

    • Final score calculated by multiplying these values

    • Expression categorized as: negative (0), low (1-4), or high (>4)

  • Five randomly selected fields of view under 400× magnification is a standard approach for scoring

• Localization assessment:

  • PBK can be localized in the nucleus, cytoplasm, or both

  • Subcellular localization should be carefully documented as it may have functional significance

How can researchers effectively validate PBK antibody specificity?

Effective validation of PBK antibody specificity is crucial for ensuring reliable research results:

• Genetic validation approaches:

  • CRISPR-Cas9 knockout validation: Generation of PBK/TOPK-KO cell lines provides the gold standard control for antibody specificity. For example, HCT-116 cells with CRISPR-mediated PBK knockout have been created using sgRNAs targeting specific PBK sequences (5′-CAGAAGCTTGGCTTTGGTAC-3′, 5′-AGGCCGGGATATTTATAGT-3′)

  • siRNA knockdown: Transient knockdown of PBK can serve as an alternative validation approach

• Biochemical validation:

  • Immunoprecipitation followed by mass spectrometry to confirm antibody captures the intended target

  • Immunoblotting should show a band at the expected molecular weight (~36-40 kDa)

  • Recombinant protein controls: Testing antibody against purified recombinant PBK protein of known concentration

• Orthogonal validation:

  • Use multiple antibodies targeting different epitopes of PBK and compare results

  • Compare antibody-based protein detection with mRNA expression data

• Experimental validation examples:

  • Western blotting: The antibody should detect a band at approximately 36-40 kDa in positive control samples (e.g., U-87 MG human glioblastoma cells)

  • Immunoprecipitation: Specific binding should be demonstrated by comparing PBK antibody IP to control IgG IP in samples known to express PBK (e.g., A431 human epidermoid carcinoma cells)

  • Immunofluorescence: Proper subcellular localization consistent with known PBK distribution (e.g., in HeLa cells)

What explains the contradictory prognostic significance of PBK/TOPK expression in different cancer types?

The contradictory prognostic significance of PBK/TOPK across different cancer types represents an intriguing area of research with several potential explanations:

• Cancer-specific biological roles:

  • In colon cancer, high PBK/TOPK expression correlates with favorable prognosis and is associated with increased immune infiltration of antitumor immune cells, including CD8+ T cells, CD4+ T cells, natural killer cells, and M1 macrophages

  • In breast cancer, overexpression of PBK/TOPK relates to poor prognosis, potentially through different molecular mechanisms

• Immune microenvironment effects:

  • PBK/TOPK expression correlates positively with antitumor immune cell infiltration in colon cancer:

    • Higher levels of CD8+ T cells

    • Increased natural killer (NK) cells

    • More CD4+ T cells

    • Greater numbers of M1 macrophages

  • Conversely, PBK/TOPK expression negatively correlates with immunosuppressive cells in colon cancer:

    • Lower levels of regulatory T (Treg) cells

    • Reduced M2 macrophages

• Genomic instability connections:

  • High PBK/TOPK expression in colon cancer is associated with mutations in DNA damage repair genes

  • This leads to increased tumor mutation burden and neoantigen load

  • Higher neoantigen burden typically makes tumors more immunogenic and potentially more responsive to immunotherapy

• T-cell cytotoxicity correlation:

  • PBK/TOPK expression correlates with expression of T-cell cytotoxicity genes in colon cancer

  • This suggests a mechanistic link between PBK/TOPK and anti-tumor immune responses

• Methodological considerations:

  • Different scoring systems and cutoff values used across studies

  • Variability in antibody clones and detection methods

  • Heterogeneous patient populations and treatment regimens

This complex interplay between PBK/TOPK expression, immune infiltration, genomic stability, and tumor-specific biology likely accounts for the observed prognostic differences across cancer types. Further research using standardized methodologies across multiple cancer types is needed to fully elucidate these mechanisms.

What are the key considerations when using PBK antibodies for cell cycle analysis research?

When investigating PBK's role in cell cycle regulation, researchers should consider several critical factors:

• Cell synchronization approaches:

  • Since PBK appears to be most active during mitosis, cell synchronization methods are essential for studying its cell cycle-specific functions

  • Techniques such as double thymidine block, nocodazole treatment, or serum starvation/release can be employed to enrich for specific cell cycle phases

• DNA damage response studies:

  • PBK forms a complex with TP53 when phosphorylated, affecting G2/M checkpoint regulation during DNA damage

  • Researchers can induce DNA damage using agents like SN-38 (as demonstrated with HCT-116 cells) to study PBK's role in this process

  • Cell cycle analysis can be performed using propidium iodide staining and flow cytometry after DNA damage induction

• Knockout/knockdown experimental design:

  • CRISPR/Cas9-mediated PBK knockout models provide valuable tools for studying PBK's cell cycle functions

  • HCT-116 PBK/TOPK-KO cell lines can be generated using specific sgRNAs (e.g., 5′-CAGAAGCTTGGCTTTGGTAC-3′, 5′-AGGCCGGGATATTTATAGT-3′)

  • Knockout clones should be validated by Western blotting to confirm complete absence of PBK protein

• Phosphorylation state analysis:

  • Since PBK's activity is regulated by phosphorylation, phospho-specific antibodies or phosphatase treatments may be necessary

  • Analysis of downstream targets (e.g., phosphorylated p38 MAPK) can provide functional readouts of PBK activity

• Cell type considerations:

  • Different cell lines show varying levels of PBK expression

  • Commonly used cell lines for PBK studies include:

    • HCT-116 (colon cancer)

    • HeLa (cervical adenocarcinoma)

    • A431 (epidermoid carcinoma)

    • U-87 MG (glioblastoma)

• Protocol example for cell cycle analysis:

  • Culture cells (e.g., wild-type and PBK/TOPK-KO HCT-116) for one day in a humidified incubator with 5% CO₂

  • Treat cells with DNA-damaging agents (e.g., SN-38) or vehicle at appropriate concentrations and time points

  • Fix cells in ice-cold 70% ethanol

  • Stain with propidium iodide solution

  • Analyze cell cycle distribution using flow cytometry

How can PBK antibodies be used to investigate the relationship between PBK expression and tumor immunity?

PBK antibodies serve as valuable tools for investigating the complex relationship between PBK expression and tumor immunity:

• Multiplex immunohistochemistry/immunofluorescence approaches:

  • Co-staining of PBK with immune cell markers (CD8, CD4, NK cell markers, macrophage markers)

  • This allows spatial analysis of PBK-expressing cells relative to tumor-infiltrating immune cells

  • Requires careful antibody panel design to avoid cross-reactivity between antibodies

• Correlation analysis with immune cell deconvolution data:

  • PBK expression levels from immunoblotting or IHC can be correlated with immune cell composition derived from transcriptomic data

  • Multiple deconvolution algorithms can be used, such as those available in the TIMER2.0 web portal, to estimate immune cell infiltration levels

  • This approach has revealed positive correlations between PBK expression and infiltration of:

    • CD8+ T cells

    • Natural killer (NK) cells

    • CD4+ T cells

    • M1 macrophages

  • And negative correlations with:

    • Regulatory T (Treg) cells

    • M2 macrophages

• Analysis of T-cell cytotoxicity genes:

  • PBK expression correlates with T-cell cytotoxicity gene expression in colon cancer

  • Researchers can investigate this relationship using antibodies against both PBK and cytotoxicity markers

• Tumor mutation burden assessment:

  • High PBK expression associates with mutations in DNA damage repair genes

  • This leads to increased tumor mutation and neoantigen burden

  • Researchers can correlate PBK antibody staining intensity with genomic data to explore this relationship

• Functional studies using PBK knockout models:

  • Generate PBK/TOPK knockout cell lines using CRISPR/Cas9

  • Compare immune cell recruitment/activation between wild-type and knockout tumors in syngeneic mouse models

  • Analyze differences in immune checkpoint molecule expression and response to immunotherapy

This multifaceted approach using PBK antibodies in conjunction with other molecular and cellular techniques can provide comprehensive insights into how PBK influences tumor immunity and potentially predicts immunotherapy response.

What are common challenges when using PBK antibodies and how can they be addressed?

Researchers may encounter several technical challenges when working with PBK antibodies:

• Nonspecific binding in Western blotting:

  • Problem: Multiple bands or high background

  • Solutions:

    • Optimize blocking conditions (try different blocking agents like 5% milk, BSA, or commercial blockers)

    • Adjust antibody concentration (typical dilutions range from 1:1000 for Western blotting)

    • Include appropriate controls (lysates from PBK knockout cells)

    • Ensure proper sample preparation to prevent protein degradation

• Poor signal in immunohistochemistry:

  • Problem: Weak or absent staining

  • Solutions:

    • Optimize antigen retrieval methods

    • Adjust antibody concentration (typical dilutions range from 1:50 for IHC)

    • Extend incubation time or perform at 4°C overnight

    • Use signal amplification systems

    • Ensure tissue fixation is appropriate (overfixation can mask epitopes)

• Inconsistent immunofluorescence results:

  • Problem: Variable cellular localization or intensity

  • Solutions:

    • Standardize fixation protocols (4% paraformaldehyde is commonly used)

    • Optimize permeabilization conditions

    • Use nuclear counterstains (e.g., Hoechst 33342) to clearly visualize nuclear localization

    • Control for cell cycle stage effects on PBK expression and localization

• Immunoprecipitation efficiency issues:

  • Problem: Poor pull-down of PBK protein

  • Solutions:

    • Optimize lysis conditions to ensure PBK solubilization

    • Adjust antibody amount (5 μg antibody has been successfully used for IP from A431 cells)

    • Consider crosslinking antibodies to beads to prevent heavy chain interference

    • Use appropriate controls (e.g., control IgG IP) to confirm specificity

• Batch-to-batch variability:

  • Problem: Inconsistent results between antibody lots

  • Solutions:

    • Purchase larger quantities of a single lot when possible

    • Validate each new lot against previous lots

    • Consider using monoclonal antibodies for greater consistency

    • Maintain detailed records of lot numbers and performance

How should researchers interpret apparent contradictions in PBK localization or expression data?

When faced with contradictory data regarding PBK localization or expression, researchers should consider several factors:

• Cell type and context specificity:

  • PBK localization can vary between cell types (nuclear, cytoplasmic, or both)

  • Cellular context (cancer vs. normal, proliferating vs. quiescent) affects expression patterns

  • Different cancer types show opposite prognostic associations with PBK expression

• Methodological differences:

  • Different fixation methods can affect epitope accessibility and apparent localization

  • Various antibodies target different epitopes, potentially revealing distinct pools of PBK

  • Scoring systems and cutoffs vary between studies:

    • Some use combined intensity and percentage scoring

    • Others may use different thresholds for defining "high" vs. "low" expression

• Biological variability:

  • Cell cycle stage affects PBK expression and localization (primarily active during mitosis)

  • Post-translational modifications (especially phosphorylation) can change antibody recognition

  • Protein complexes may mask certain epitopes in specific cellular contexts

• Resolution approach:

  • Use multiple antibodies targeting different PBK epitopes to confirm findings

  • Employ complementary techniques (e.g., fractionation plus Western blotting along with immunofluorescence)

  • Ensure proper experimental controls, including:

    • PBK knockout or knockdown samples

    • Cell cycle synchronization when appropriate

    • Positive control samples with known PBK expression patterns

• Data integration strategies:

  • Correlate protein expression data with mRNA expression

  • Consider genomic and proteomic data together

  • Integrate findings with functional studies to determine biological significance

By systematically addressing these factors, researchers can better interpret apparently contradictory findings and develop a more complete understanding of PBK biology in their specific research context.